A Multi-center, Randomized, Double-blind, Parellel Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy in Patients With Hypertension and Primary Hypercholesterolemia.

NCT02770261 Phase 3 COMPLETED

The purpose of this study is to determine superiority of DP-R208 compare to each monotherapy in patient with hypertension and primary hypercholesterolemia.

Details

Lead sponsor	Alvogen Korea
Phase	Phase 3
Status	COMPLETED
Enrolment	219
Start date	2015-12
Completion	2016-10

Conditions

• Hypertension
• Cholesterolemia

Interventions

• DP-R208
• Candesartan32mg
• Rosuvastatin 20mg
• DP-R208 Placebo
• Candesartan32mg Placebo
• Rosuvastatin 20mg Placebo

Primary outcomes

• Mean change of mean seated Systolic Blood Pressure and Percent change of LDL cholesterol — 8weeks

Countries

South Korea